GlycoMimetics, Inc. (GLYC)

NASDAQ: GLYC · IEX Real-Time Price · USD
2.29
+0.15 (7.01%)
Dec 2, 2022 4:00 PM EST - Market closed
7.01%
Market Cap 112.19M
Revenue (ttm) 92,625
Net Income (ttm) -53.87M
Shares Out 52.42M
EPS (ttm) -1.23
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 876,179
Open 2.13
Previous Close 2.14
Day's Range 2.09 - 2.38
52-Week Range 0.51 - 2.43
Beta 1.86
Analysts Buy
Price Target 8.16 (+256.3%)
Earnings Date Nov 9, 2022

About GLYC

GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as in phase 3 trial to treat relapsed/refractory AML. In addition, the company is developing GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of cancers that affect ... [Read more]

Industry Biotechnology
IPO Date Jan 10, 2014
CEO Rachel King
Employees 52
Stock Exchange NASDAQ
Ticker Symbol GLYC
Full Company Profile

Financial Performance

In 2021, GlycoMimetics's revenue was $1.16 million, a decrease of -88.59% compared to the previous year's $10.16 million. Losses were -$63.43 million, 24.3% more than in 2020.

Financial Statements

Analyst Forecast

According to 9 analysts, the average rating for GLYC stock is "Buy." The 12-month stock price forecast is 8.16, which is an increase of 256.33% from the latest price.

Price Target
$8.16
(256.33% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Is GlycoMimetics (GLYC) Outperforming Other Medical Stocks This Year?

Here is how GlycoMimetics (GLYC) and Axonics Modulation Technologies (AXNX) have performed compared to their sector so far this year.

2 days ago - Zacks Investment Research

After Golden Cross, GlycoMimetics (GLYC)'s Technical Outlook is Bright

Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?

1 week ago - Zacks Investment Research

GlycoMimetics (GLYC) Upgraded to Buy: Here's Why

GlycoMimetics (GLYC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

2 months ago - Zacks Investment Research

GlycoMimetics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (the “Company”) (NASDAQ:GLYC) today announced that the compensation committee of the Company's Board of Directors approved the grant on September 2, ...

2 months ago - Business Wire

GlycoMimetics to Participate in Upcoming H.C. Wainwright 24th Annual Global Investment Conference

ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that Harout Semerjian, Chief Executive Officer, will present in-person at the H.C. Wainwright 24th Annual Global Inves...

2 months ago - Business Wire

GlycoMimetics Appoints Edwin Rock, M.D., Ph.D. as Chief Medical Officer

ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC), a clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases,...

2 months ago - Business Wire

What Makes GlycoMimetics (GLYC) a New Buy Stock

GlycoMimetics (GLYC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

3 months ago - Zacks Investment Research

GlycoMimetics Reports Highlights and Financial Results for Second Quarter 2022

ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) today reported its financial results and highlights for the second quarter ended June 30, 2022. Cash and cash equivalents as of the en...

4 months ago - Business Wire

GlycoMimetics to Report Second Quarter Financial Results on August 3, 2022

ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC), today announced that it will host a conference call and webcast to report second quarter financial results on Wednesday, August 3, 20...

4 months ago - Business Wire

GlycoMimetics to Participate at Upcoming Jefferies 2022 Healthcare Conference

ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that the Company will participate at the Jefferies 2022 Healthcare Conference, on June 8th, in New York, NY. Chief Exe...

6 months ago - Business Wire

GlycoMimetics Reports Highlights and Financial Results for First Quarter 2022

ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) today reported its financial results and highlights for the first quarter ended March 31, 2022. Cash and cash equivalents at March 31,...

7 months ago - Business Wire

GlycoMimetics to Report First Quarter Financial Results on April 28, 2022

ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC), today announces that it will host a conference call and webcast to report first quarter financial results on Thursday, April 28, 2022...

7 months ago - Business Wire

GlycoMimetics to Participate at Upcoming Roth Investor Conference

ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that the Company will participate at the 34th Annual Roth Conference in Laguna Niguel, California, March 14 and 15. Ch...

8 months ago - Business Wire

GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Full Year 2021

ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) today reported its financial results and highlights for the fourth quarter and year ended December 31, 2021. Cash and cash equivalents...

9 months ago - Business Wire

GlycoMimetics Appoints Deepak Tiwari, Ph.D., as new Vice President, Technical Operations

ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) announced today that Dr. Deepak Tiwari has joined the Company as Vice President, Technical Operations. “Dr. Tiwari brings over 25 year...

9 months ago - Business Wire

GlycoMimetics to Report Fourth Quarter and 2021 Year-End Financial Results on March 3, 2022

ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) announced today that it will host a conference call and webcast to report its fourth quarter and 2021 year-end financial results on Th...

9 months ago - Business Wire

GlycoMimetics Appoints Bruce Johnson Senior Vice President and Chief Commercial Officer

ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) announced today that Bruce Johnson has joined its executive leadership team as Senior Vice President and Chief Commercial Officer. “Br...

9 months ago - Business Wire

Two GlycoMimetics Posters at 63rd ASH Annual Meeting Highlight Potential of GMI-1359, a Dual Antagonist of CXCR4 and ...

ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) this week at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition in Atlanta presented two posters providing su...

11 months ago - Business Wire

NCI-Sponsored Trial of Uproleselan in Older, Newly Diagnosed AML Patients Fit for Intensive Chemotherapy Completes En...

ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC), a clinical-stage biotechnology company, announced today that the National Cancer Institute (NCI), part of the National Institutes of ...

11 months ago - Business Wire

Apollomics Inc. Doses First Patient in Phase 3 Clinical Trial in China of GlycoMimetics' Uproleselan for the Treatmen...

ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) announced today that Apollomics has dosed the first patient in China in a Phase 3 clinical trial of APL-106 (uproleselan injection) fo...

1 year ago - Business Wire

GlycoMimetics Appoints Regulatory Veteran Lisa DeLuca as Vice President, Regulatory Affairs

ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) announced today that Lisa DeLuca, Ph.D., has joined its executive leadership team as Vice President, Regulatory Affairs. Dr. DeLuca is...

1 year ago - Business Wire